This review will describe the mechanisms of CTLA-4 immune checkpoint inhibition, the role of Treg cells in tumorigenesis, and how anti-CTLA-4 antibodies can provoke an alteration in the expression of CTLA-4 on Treg cells while exerting anti-cancer therapeutic activity. The gene discussed is CTLA4; the disease is cancer.